Daiichi Sankyo Completes Sale of Sun Pharma Shares

Daiichi Sankyo Completes Sale of Sun Pharma Shares

Tokyo, Japan (April, 21, 2015) - Following the announcement yesterday that Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) decided to sell the entire or part of its holdings of Sun Pharmaceutical Industries Ltd. (hereafter, Sun Pharma) shares, Daiichi Sankyo today announced that the sale of Sun Pharma shares has been completed as stated below.

1. Change in the number of shares held after the sale

(1) Number of shares held before the sale

(As of April 20, 2015)

214,969,058 shares

(2) Shares sold

214,969,058 shares

(3) Number of shares held after the sale

0 shares

2. Impact on financial results

Daiichi Sankyo will make an announcement concerning the effect of any gain or loss on the sale of Sun Pharma shares when results of operations for the fiscal year ending in March 2015 are announced.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.